Elanco Expects Retail Growth In 2027 Even As Costco Contract Ends

Dollar General and other distribution partners are expected to offset Costco’s pullback, with the impact concentrated in the first quarter.

Share
Elanco Expects Retail Growth In 2027 Even As Costco Contract Ends

Elanco Animal Health, which makes medicines and vaccines for pets and farm animals, expects retail growth in 2027 despite Costco’s decision not to renew its agreement, President and Chief Executive Officer Jeff Simmons said on the company’s earnings call Friday. Management expects the loss of Costco business to affect primarily the first quarter, with other retailers offsetting the pullback.

Dollar General Helps Fill The Gap

Simmons pointed to Dollar General and additional distribution partners secured since last quarter as the basis for his retail outlook. Responding to a UBS analyst, management confirmed that the contract established this year would end for next year.

“We see net-net being positive on the retail side in 27, but Costco will not be a player in that,” Simmons said.

The non-renewal does not end Simmons’ expectations for future business with the retailer. Answering a Stifel analyst, he said, “We expect a long-term relationship with Costco,” while describing the coming year as a pullback.

Elanco’s distribution strategy extends beyond replacing an individual retailer. Simmons said one-third of pet owners do not regularly visit a veterinarian, making additional outlets and nonprescription products a way to reach customers outside clinics.

Clinic Growth Outruns Retail Weakness

The retail challenge comes against a stronger pet-health business. U.S. pet-health revenue grew 13% on an organic, constant-currency basis in the third quarter even though retail sales were slightly negative. Simmons said retailer inventory reductions partly affected Seresto sales, while the brand’s consumption trends were slightly positive for the year to date.

Elanco sells parasite-control, skin-treatment, vaccine and pain-relief products for dogs and cats, including Advantage, Seresto and Credelio. Its customers include distributors, retailers and veterinarians; the broader business also supplies products for cattle, poultry, swine and sheep.

Simmons argued that willingness to spend and shopping convenience matter more than veterinary-visit volumes as indicators of pet-health demand. In Elanco’s October survey of more than 1,500 U.S. pet owners, 93% said they had maintained or increased spending over the past three months and planned to continue doing so. Simmons said spending was shifting toward more convenient purchasing options.

A Higher Outlook Before February

Chief Financial Officer Bob VanHimbergen said Elanco raised its full-year organic, constant-currency revenue-growth outlook to approximately 8%, from 6%–7%. That measure excludes foreign-exchange effects, acquisitions, divestitures and the royalty revenue and sales-based milestones sold to a third party.

The higher outlook followed third-quarter revenue of $1.265 billion, up 11% as reported and 9% on an organic, constant-currency basis. Volume contributed 5% growth and pricing contributed 4%.

For 2027, management reaffirmed targets of about 5% organic, constant-currency revenue growth, under 10% growth in adjusted earnings before interest, taxes, depreciation and amortization, and a little over 10% growth in adjusted earnings per share. VanHimbergen expects pet health to grow faster than farm animal.

Elanco plans to issue formal 2027 guidance in February, when management will put financial ranges around a year that includes Costco’s non-renewal.

Sources

More on Elanco Animal Health

All Elanco Animal Health (ELAN) coverage →